Echinaforce COVID-19 Shedding Study

Last updated: August 5, 2024
Sponsor: A. Vogel AG
Overall Status: Terminated

Phase

4

Condition

Respiratory Syncytial Virus (Rsv) Infection

Covid-19

Treatment

Echinaforce Chewable tablets

Echinaforce Forte tablets

Echinaforce tincture

Clinical Study ID

NCT04999098
5'000'820
  • Ages 12-75
  • All Genders

Study Summary

Respiratory viruses pose a permanent threat to humans and society as demonstrated by the current Covid-19 pandemic. Novel drugs and vaccines provide a means for controlling illness. Infections and symptomatic presentation of illness may be reduced, but it remains to be determined to which extent viral shedding and transmission (e.g. by silent transmitters) can be controlled. Lack of such activity may result in continuing viral spread by assumed healthy but asymptomatic spreaders. Echinacea is an established and readily-accessible product with demonstrated in vitro antiviral activity (including coronaviruses). This study aims to estimate the potential of different Echinacea formulations (head-to-head) to reduce concentration infectivity and shedding of SARS-CoV-2 under in vivo conditions.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 12 - 75 years.

  • Written informed consent.

  • Ability and willingness to give oropharyngeal swab samples.

  • Positive pre-screening SARS-CoV-2 RT-PCR virus test with an above threshold viralload as per qPCR (Cq ≤ 27).

Exclusion

Exclusion Criteria:

  • ≥76 years

  • <12 years.

  • Participation in another clinical study in the past 30 days or planned during studyconduct.

  • Severe COVID19

  • Intake of antimicrobial, antiviral, immune suppressive substances.

  • Surgical intervention in the 3 months prior enrolment

  • Known diabetes mellitus.

  • Known and medicated atopy or asthma.

  • Cystic Fibrosis, bronchopulmonary dysfunction, COPD.

  • Known immune system disorders and degenerative disorders (autoimmune disorders,AIDS, leukemia, lymphoma, myeloma).

  • Known metabolic or resorption disorders.

  • Known liver or kidney illnesses (chronic hepatitis, liver cirrhosis, chronic kidneyinsufficiency).

  • Serious health conditions (limited general condition, auto-immune diseases, tumorousdiseases, neurological disorders or serious Covid-19)

  • Known allergies to plants of the compositae family (e.g. chamomile or dandelion) orto one of the compounds in the investigational product

  • Known pregnancy.

Study Design

Total Participants: 40
Treatment Group(s): 3
Primary Treatment: Echinaforce Chewable tablets
Phase: 4
Study Start date:
November 15, 2021
Estimated Completion Date:
August 15, 2023

Connect with a study center

  • Diagnostics and Consultation Center Convex EOOD

    Sofia, 1680
    Bulgaria

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.